05-345
Anti-p21/WAF1/Cip1 Antibody
Upstate®, from mouse
Synonyme(s) :
CDK-interacting protein, CDK-interaction protein, DNA synthesis inhibitor, Melanoma differentiation-associated protein 6, cyclin-dependent kinase inhibitor 1A, melanoma differentiation associated protein 6, wild-type p53-activated fragment 1
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
CP36, monoclonal
CP74, monoclonal
Espèces réactives
mouse, human
Fabricant/nom de marque
Upstate®
Technique(s)
immunoprecipitation (IP): suitable
western blot: suitable
Isotype
IgG
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
dry ice
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... CDKN1A(1026)
Description générale
Two families of cyclin dependent kinase inhibitors (CKIs) have been identified. The p21WAF1/Cip1 family inhibits all kinases involved in the G1/S transition. The p16INK4a family inhibits Cdk4 and Cdk6 specifically. The biochemical activities and patterns of expression of CKIs during development implicate these proteins as the primary effectors of signaling pathways that control cell cycle exit, an event that is critical for differentiation. Studies have shown that p21WAF1/Cip1 binds tightly to the G1 and S phase kinases, cyclin E/Cdk2, cyclin D/Cdk4, and cyclin A/Cdk2, and effectively inhibits their activity, whereas p21WAF1/Cip1 is a relatively poor inhibitor of the G2/M phase kinase cyclin B/Cdc2. In addition, p21WAF1/Cip1 inhibits proliferating cell nuclear antigen (PCNA), binds to and inhibits inactivation of Rb, which is essential for cell cycle progression, and may also interact with E2F and protect cells against p53-mediated apoptosis.
Spécificité
Other species cross-reactivity is unknown.
Recognizes Cip1, MW 21 kDa
Immunogène
Epitope: amino acids 1-80
Recombinant full-length human Cip1 with a histidine tag.
Application
Immunoprecipitation: 4 μg of a previous lot immunoprecipitated Cip1 from 500 μg of HeLa nuclear extract.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair
Cell Cycle, DNA Replication & Repair
Use Anti-p21/WAF1/Cip1 Antibody (Mouse Monoclonal Antibody) validated in WB, IP to detect p21/WAF1/Cip1 also known as CDK-interacting protein or cyclin-dependent kinase inhibitor 1A.
Qualité
Evaluated by western blotting on HeLa nuclear extract.
Western Blot Analysis: 0.5-2 μg/mL of this antibody detected Cip1 in 20 μg of HeLa nuclear extract
Western Blot Analysis: 0.5-2 μg/mL of this antibody detected Cip1 in 20 μg of HeLa nuclear extract
Description de la cible
21 kDa
Forme physique
Format: Purified
Protein G Purified
Purified, pooled monoclonal mouse IgGs in buffer containing 0.1 M Trisglycine, pH 7.4, 0.15 M NaCl containing 0.05% sodium azide. Frozen solution.
Stockage et stabilité
Stable for 1 year at from date of receipt.
Remarque sur l'analyse
Control
Positive Antigen Control: Catalog #12-309, Hela cell nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 10 μL of extract and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced extract per lane for minigels.
Positive Antigen Control: Catalog #12-309, Hela cell nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 10 μL of extract and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced extract per lane for minigels.
Autres remarques
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informations légales
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
En option
Réf. du produit
Description
Tarif
Code de la classe de stockage
12 - Non Combustible Liquids
Classe de danger pour l'eau (WGK)
WGK 1
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Georg Nickenig et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 16(9), 1077-1086 (2002-06-28)
Reactive oxygen species such as superoxide and hydroxyl radicals have been implicated in the pathogenic growth of various cell types. The molecular mechanisms involved in redox-sensitive cell growth control are poorly understood. Stimulation of cultured vascular smooth muscle cells (VSMC)
Histone deacetylase is a target of valproic acid-mediated cellular differentiation.
Gurvich, Nadia, et al.
Cancer Research, 64, 1079-1086 (2004)
CREG1 enhances p16(INK4a) -induced cellular senescence.
Moolmuang, B; Tainsky, MA
Cell Cycle null
M Pibiri et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 15(6), 1006-1013 (2001-04-09)
The thyroid hormone (T3) affects cell growth, differentiation, and regulates metabolic functions via its interaction with the thyroid hormone nuclear receptors (TRs). The mechanism by which TRs mediate cell growth is unknown. To investigate the mechanisms responsible for the mitogenic
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
Inoue, Hiromi, et al.
Cancer Biology & Therapy, 12, 827-836 (2011)
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique